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This study aimed to evaluate the clinical analgesic efficacy and identify the molecular targets of XGDP for treating primary
dysmenorrhea (PD) by a network pharmacology approach. Analysis of pain disappearance rate of XGDP in PD treatment was
conducted based on data from phase II and III randomized, double-blind, double-simulation, and positive parallel controlled
clinical trials. The bioactive compounds were obtained by the absorption, distribution, metabolism, and excretion processes with
oral bioavailability (OB) and drug-likeness (DL) evaluation. Subsequently, target prediction, pathway identification, and network
constructionwere employed to clarify themechanisms of the analgesic effect of XGDP on PD.The pain disappearance rates in phase
II and III clinical trials of XGDP in PD treatment were 62.5% and 55.8%, respectively, yielding a significant difference (𝑃 < 0.05)
when compared with the control group using Tongjingbao granules (TJBG). Among 331 compounds, 53 compounds in XGDPwere
identified as the active compounds related to PD through OB, DL, and target prediction. The active compounds and molecular
targets of XGDP were identified, and our study showed that XGDP may exert its therapeutic effects on PD through the regulation
of the targets related to anti-inflammation analgesia and central analgesia and relieving smooth muscle contraction.
1. Introduction
Primary dysmenorrhea (PD) is a common gynecological
complaint in adolescent girls and young women. It is char-
acterized by lower abdominal pain and often accompanied
by symptoms such as sweating, headache, nausea, vomiting,
diarrhea, and tremulousness [1, 2]. Dysmenorrhea is com-
mon in adolescents, affecting up to 93% of the population
[3]. Nonsteroid anti-inflammatory drugs (NSAIDs) are very
effective for treating dysmenorrhea; however, NSAIDs are
usually associated with many adverse effects including indi-
gestion, headaches, and drowsiness [4].
Traditional Chinese Medicine (TCM) has been widely
used in China to prevent, diagnose, and treat diseases over
2,000 years. Many Chinese medicines (CMs) have been used
for treating PD and were proved to be effective without
obvious side effects [5, 6]. Therefore, TCMs, including single
herb and combination formulas, are perhaps the ideal thera-
peutics for treating PD [7]. Xuangui Dropping Pill (XGDP),
which is a Chinese patent medicine, has been approved by
China Food and Drug Administration (approval number
Z20130008) and is widely used for treating dysmenorrhea in
China.
XGDP is a modified classic TCM formula that is derived
from the Xuangui Decoction in the Song dynasty Shenghui
Prescription. Xuangui Decoction in TCM can activate blood
circulation, dissipate stasis, and relieve pain and has been
commonly used for the treatment of irregular menses and
algomenorrhea. XGDP is composed of three Chinese medic-
inal herbs, namely, Corydalis Rhizoma (CR, Yanhusuo),
Angelica Sinensis Radix (ASR, Danggui), and Zingiberis
Rhizoma (ZR, Ganjiang). Among these three herbs, CR is a
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common herb that has been used as an analgesic in TCM for
thousands of years [8], and modern pharmacological studies
have shown that XGDP is a potential anti-inflammatory agent
and analgesic [9, 10].
In recent years, much attention has been paid to TCM
monomers and compounds. For example, the constituents
in rat plasma after oral administration of CR were analyzed
and identified using liquid chromatography-mass spectrom-
etry/mass spectrometry [11]. However, the active substances
and specific molecular mechanisms of the analgesic effect of
XGDP for treating PD are still unclear.
A TCM formula is a complex combination with multiple
components, multiple targets, and synergistic interactions
among its components [12]. Because of the complex chemical
composition, it is extremely difficult to study the role of the
mixture system in the body.The complexity of TCM formulas
makes it difficult to conduct a comprehensive study of TCM,
whereas systems pharmacology [13] provides new ideas and
perspectives for the study of Chinese herbal compounds.
Identification of the active substances of TCM and their
corresponding molecular targets and the determination of
the relationship between active substances and diseases by
using systems pharmacology [13] and network pharmacology
[14] can help elucidate themolecularmechanisms of action of
TCM formulas. For orally administered TCM formulas, the
ingredients in the TCM formula must first overcome the bar-
riers posed by the absorption, distribution, metabolism, and
excretion (ADME) processes, and only the ingredients that
can pass through the barriers may be active ingredients [15].
These ingredients can bind to the targets in the body and thus
achieve efficacy by interacting with the human body at the
network level and the overall organ level. The network phar-
macology is applied to the study of TCM by combining oral
bioavailability, drug-likeness screening, target identification,
and network construction and analysis. The TCM network
pharmacology not only offers an opportunity to discover
bioactive ingredients and drug targets but also reveals the
mechanisms of action between a TCM formula and the rel-
evant diseases. For example, previous studies by the team of
Yonghua Wang successfully applied TCM network pharma-
cology in the prediction of the active ingredients and poten-
tial targets [16], uncovering the molecular mechanism of
medicinal herbs [17, 18] and the synergistic mechanisms [19].
Therefore, in this study, we first evaluated the analgesic
efficacy of XGDP in PD treatment based on data from phase
II and III clinical trials. Then, on the basis of the ADME
processes, we identified the active molecules of the XGDP
formula that pass across the body barrier and predicted the
network targets of the active substances. We also proposed
its mechanisms of action on analgesia, which may provide
a basis for an in-depth understanding of the mechanisms of
action of XGDP for treating PD. Figure 1 shows the workflow
of network pharmacological study of XGDP.
2. Materials and Methods
2.1. Design of Clinical Trial. The clinical data in this study
originated from phase II and III clinical trials before the
approval of XGDP for sale. A randomized, double-blind,
double-simulation, positive parallel controlled, and multi-
center design was used in both clinical trials. Tongjingbao
granules (TJBG) were used as a positive control drug. The
TJBG has been approved by the China Food and Drug
Administration (approval number Z41021972) and has anal-
gesic and anti-inflammatory effects in treating dysmenorrhea
[20]. The symptoms of the 240 and 480 patients with PD
pain during the phase II and III clinical trials, respectively,
were all consistent with the western medicine diagnosis
of PD, as well as the TCM diagnosis of cold coagulation
and blood stasis. The medicine sampled in this study was
approved by the CFDA (approval number 2004L00160). The
study protocol was approved by the ethics committee of the
Affiliated Hospital of Hubei University of Chinese Medicine
before study commencement. Each participant was informed
of the purpose, processes, benefits, and risks of the study and
signed a consent form.
2.2. Treatment Method. The treatment groups were given ten
XGDP grains thrice per day; at the same time, they also took
one packet of TJBG simulation agent thrice per day. The
control group was given one packet of TJBG thrice per day;
at the same time, they took ten grains of XGDP simulation
agent thrice a day.The participants started their medication 3
days before their menstruation for 10 consecutive days.Three
menstrual cycles constituted a single treatment.
2.3. Primary Outcome and Statistical Analysis. The primary
outcome of the study was the pain disappearance rate. A
full analysis set was used and all randomized participants
were included in the analysis. A chi-square test was used to
compare the differences between the two groups, with 𝑃 ≤
0.05 being the indicator of a statistically significant difference.
The statistical analysis software used was SAS 9.3 (SAS Inst.,
Inc., Cary, NC, USA).
2.4. Candidate Compound Identification. Compound infor-
mation of XGDP was retrieved from the Traditional Chinese
Medicine Systems Pharmacology Database and Analysis
Platform (TCMSP), which includes information of all 500
Chinese herbal medicines registered in the Chinese Phar-
macopoeia (2010 edition) with a total of 30,069 ingredients
collected through literature mining and database integra-
tion. Comprehensive data related to the pharmacokinetic
properties of each chemical compound, comprising oral
bioavailability (OB), intestinal epithelial permeability (Caco-
2), drug likeness (DL), blood-brain barrier (BBB), drug half-
life (HL), and Lipinski’s rule (LR) of five, are provided for the
screening and evaluation of the compounds [15].
2.5. Active Compound Screening. OB is one of the most
crucial pharmacokinetic parameters in the ADME processes
[21]. High OB is often used as the key indicator to determine
the drug-like property of bioactive molecules. Most of the
ingredients in TCMs fail to reach the protein target sites of
particular cells because of the lack of appropriate pharma-
cological properties, particularly OB. In the present study,
the molecules with OB ≥ 30% were considered to exhibit
favorable OB.
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Figure 1: The workflow of the network pharmacological study of XGDP.
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Table 1: Demographic characteristics.
Characteristics XGDP group TJBG group 𝑃 value
Phase II study 𝑁 = 120 𝑁 = 120
Age (yr) 22.92 ± 3.04 22.73 ± 2.53 0.613
Height (cm) 161.12 ± 4.66 160.80 ± 4.60 0.597
Weight (kg) 51.04 ± 5.39 50.58 ± 5.97 0.526
Course of disease (yr) 6.61 ± 3.47 6.02 ± 3.19 0.170
Phase III study 𝑁 = 360 𝑁 = 120
Age (yr) 22.55 ± 3.28 22.95 ± 3.40 0.249
Height (cm) 161.42 ± 4.61 160.80 ± 4.65 0.206
Weight (kg) 52.12 ± 5.73 51.51 ± 5.95 0.320
Course of disease (yr) 5.03 ± 3.24 5.69 ± 3.99 0.100
In the early stages of drug development, the evaluation
of DL helps to screen excellent compounds [16] and increases
the hit rate of drug candidates.Therefore, in this study, theDL
of the molecules in XGDP was assessed using the Tanimoto
coefficient [22] through the following formula:
𝑇 (𝑋, 𝑌) =
𝑥 ∗ 𝑦
𝑥2 + 𝑦2 − 𝑥 ∗ 𝑦
, (1)
where 𝑥 is the molecular descriptor of XGDP on the basis of
Dragon software (TALETE) and 𝑦 is the average descriptor
of all drugs in the DrugBank database. Thus, in this study,
the active molecules were defined as those with DL indices
≥0.15.The compoundswith aDL index>0.15 were considered
to exhibit more favorable DL and were selected as candidate
molecules for further study.
2.6. Identification of Associated Proteins and Gene Names.
The protein targets of the compounds were retrieved from
the TCMSP database (http://lsp.nwu.edu.cn/tcmsp.php).The
dataset used for building these models included 6511 drug
molecules and 3987 targets with known compound–protein
interactions in the DrugBank database [15]. The UniProt
Knowledgebase (UniProtKB) is a protein database par-
tially curated by experts and contains 54,247,468 sequence
entries. Furthermore, the gene names were extracted from
UniProtKB (http://www.uniprot.org). Finally, the targets
were mapped to the Therapeutic Target Database (TTD,
http://database.idrb.cqu.edu.cn/TTD/) to obtain the targets
related to their corresponding diseases.
2.7. Identification of Significant Pathways. The Database
for Annotation, Visualization, and Integrated Discovery
(DAVID) bioinformatics resource comprises an integrated
online biological knowledge base and analytical tools for
systematically extracting biological data from large gene and
protein lists (http://david.abcc.ncifcrf.gov/). In this study,
to identify the pathways targeted by the compounds, the
obtained genes were further analyzed usingDAVID v6.7 [23].
Threshold count ≥2 and EASE scores ≤0.05 were selected in
functional annotation clustering.
2.8. Network Construction and Analysis. The compound–tar-
get networkwas constructed using candidate compounds and
potential targets. The target–pathway network was generated
by linking the potential targets and the signaling pathways
in which they participated. The networks were constructed
using Cytoscape 3.3.0 software [24]. In this bilateral network,
the nodes present the compounds, potential targets, or signal
pathways, and the edges present the compound–target or
target–pathway interactions.
3. Results
3.1. Demographic Characteristics. A total of 240 patients
with PD were enrolled in the phase II clinical trial. 120
patients were randomized into the XGDP group; 116 of them
completed the study and 4 of them dropped out. The other
120 patients were randomized into the TJBG group; 116 of
them completed the study and 4 of them dropped out. The
average ages of the XGDP and TJBG groups were 22.92 and
22.73 years, respectively; their respective average heights were
161.12 and 160.80 cm; their respective average weights were
51.04 and 50.58 kg; and their respective average courses of
disease were 6.61 and 6.02 years (Table 1). There was no
significant difference in demographic data between the two
groups (𝑃 > 0.05).
Among the 480 patients with PDwhowere enrolled in the
phase III clinical trial, 360 were randomized into the XGDP
group, of whom 350 patients completed the study and 10
patients dropped out. A total of 120 patients were randomized
into the TJBG group, with 116 of them completing the study
and 4 of them dropping out. The average ages of the XGDP
and TJBG groups were 22.55 and 22.95 years, respectively;
their respective average heights were 161.42 and 160.80 cm;
their respective average weights were 52.12 and 51.51 kg; and
their respective average courses of disease were 5.03 and
5.69 years (Table 1). There was no significant difference in
demographic data between the two groups (𝑃 > 0.05).
3.2. Pain Efficacy Analysis. For 240 patients with PD who
were enrolled in the phase II clinical trial, after three months
of medication, 75 out of the 120 patients in the treatment
group experienced abdominal pain relief with a 62.5% pain
disappearance rate, compared with 56 out of the 120 patients
in the control group with a 46.7% pain disappearance rate.
The difference in the pain disappearance rate between the
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Figure 2: Analysis of pain disappearance rate of XGDP in PD pain
treatment.
two groups was significant (𝑃 < 0.05). For 480 patients
with PD who were enrolled in the phase III clinical trial
with three months of medication, 201 out of the 360 patients
in the treatment group experienced abdominal pain relief,
achieving a 55.8% pain disappearance rate, compared with 45
out of the 120 patients in the control group, achieving a 37.5%
pain disappearance rate (Figure 2). The difference in pain
disappearance rate between the two groups was significant
(𝑃 < 0.05).
3.3. Identification of Active Compounds of XGDP. A total of
350 compounds of XGDP were retrieved from the TCMSP
database, comprising 77 in CR, 125 in ASR, and 148 in ZR.
The three herbs shared the same 19 compounds (Supple-
mentary 1, in the Supplementary Material available online at
https://doi.org/10.1155/2017/7525179). Of the 77 compounds
in CR, 54 satisfied the criteria of OB ≥ 30%, and 48
satisfied the criteria of OB ≥ 30% and DL ≥ 0.15. Of the
125 compounds in ASR, 69 satisfied the criteria of OB ≥
30%, and 3 satisfied the criteria of OB ≥ 30% and DL ≥
0.15. Of the 148 compounds in ZR, 58 satisfied the criteria
of OB ≥ 30%, and 6 satisfied the criteria of OB ≥ 30%
and DL ≥ 0.15. Among the 350 compounds, a total of 57
satisfied all aforementioned conditions (Table 2), and 55
compounds were obtained after removal of the duplicates.
Many compounds of XGDP exhibited favorable OB, that is,
77.1%, 55.2%, and 39.1% of compounds in CR, ASR, and ZR,
respectively. Moreover, 62.3% of compounds in CR exhibited
favorable DL; however, a low percentage of compounds in
ASR and ZR exhibited favorable DL.
The details of the 55 compounds are presented in Table 3.
Notably, the medicinal herbs of CR and ASR both contained
Table 2: Number of compounds in XGDP that satisfied OB ≥ 30%
and DL ≥ 0.15.
Herbs Total OB ≥ 30% DL ≥ 0.15
CR 77 54 (77.1) 48 (62.3)
ASR 125 69 (55.2) 3 (2.4)
ZR 148 58 (39.1) 6 (4.1)
stigmasterol, and both ASR and ZR contained beta-sitosterol
(Table 3).
For 55 compounds, most of the active compounds
have been validated to display vital biological activities
including analgesic and anti-inflammatory activities. For
instance, tetrahydropalmatine (MOL016, OB = 73.94, DL =
0.64), corydaline (MOL022, OB = 65.84, DL = 0.68), and
dehydrocorybulbine (DHCB) (MOL030, OB = 46.97, DL =
0.63) with favorable pharmacokinetic profiles come from
CR, and they have a range of pharmacological properties
including analgesic and anti-inflammatory activities [25–27].
Furthermore, stigmasterol (MOL124, OB = 43.83, DL = 0.76)
and beta-sitosterol (MOL303, OB = 36.91, DL = 0.75), a main
dietary phytosterol, may have anti-inflammatory effects via
interfering with prostaglandin metabolism [28]. 6-Gingerol
(MOL239, OB = 35.64, DL = 0.16) from ZR significantly
inhibited the tumor necrosis factor-a (TNF-a) [29].
3.4. Identification of Targets of XGDP. For the 55 compounds,
1143 targets were obtained from the TCMSP (Supplementary
2), and 217 targets were finally obtained after removal of
the duplicates. Subsequently, the targets were mapped to
the TTD. Finally, 21 targets associated with dysmenorrhea
were reserved (Table 4), and 53 compounds were finally
obtained after removal of 2 candidate compounds (MOL303
and MOL304) without any relevant targets. The 53 candidate
compounds and all their 21 potential targets were applied to
generate a graph of compound–target interactions including
73 nodes (53 compounds and 21 targets) and 271 edges (Fig-
ure 3). The centralization and heterogeneity of the network
were found to be 0.637 and 1.255, respectively. This finding
indicates that some nodes are more concentrated in the
network than others; that is, the compound–target space is
biased toward certain compounds and targets. As shown in
Figure 3, MOL042 (leonticine) displays the highest number
of target interactions (degree = 12), followed by MOL124
(stigmasterol, degree = 11), MOL011 ((S)-scoulerine, degree
= 10), MOL068 (isocorypalmine, degree = 9), MOL022
(corydaline, degree = 9), MOL020 (clarkeanidine, degree =
9), andMOL016 (tetrahydropalmatine, degree = 9). TCM is a
multicomponent complex system; one component might act
onmultiple targets and act synergistically to treat diseases. In
terms of target analysis, the targets showing a high degreemay
play a crucial role in the pharmacological function of XGDP.
For instance, PTGS2 (degree = 52) was a major therapeutic
target in inflammatory disease [30, 31]. SCN5A (degree = 44)
was inhibited to be used for pain treatment which mediates
the voltage-dependent sodium ion permeability of excitable
membranes [32]. Both OPRD1 (delta-type opioid receptor)
and OPRM1 (mu-type opioid receptor) corresponded to 28
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Table 3: Information on candidate active compounds from CR, ASR, and ZR herbs.
Number Molecule name OB (%) DL PubChem CID Herbs
MOL003 Berberine 36.86 0.78 2353 CR
MOL005 Coptisine 30.67 0.86 72322 CR
MOL006 Cryptopine 78.74 0.72 72616 CR
MOL007 Dihydrochelerythrine 32.73 0.81 485077 CR
MOL008 Dihydrosanguinarine 59.31 0.86 124069 CR
MOL009 Sanguinarine 37.81 0.86 5154 CR
MOL011 (S)-Scoulerine 32.28 0.54 439654 CR
MOL012 Cavidine 35.64 0.81 193148 CR
MOL014 (R)-Canadine 55.37 0.77 443422 CR
MOL016 Tetrahydropalmatine 73.94 0.64 72301 CR
MOL017∗ (−)-Alpha-N-methylcanadine 45.06 0.8 N/A CR
MOL018∗ Capaurine 62.91 0.69 94149 CR
MOL020∗ Clarkeanidine 86.65 0.54 127376 CR
MOL022∗ Corydaline 65.84 0.68 101301 CR
MOL023∗ Corydalmine 52.5 0.59 161665 CR
MOL024∗ Corydine 37.16 0.55 10153 CR
MOL025∗ 18797-79-0 46.06 0.85 177014 CR
MOL026∗ Corynoloxine 38.12 0.6 101324793 CR
MOL027∗ Methyl-[2-(3,4,6,7-tetramethoxy-1-phenanthryl)ethyl]amine 61.15 0.44 11462401 CR
MOL029∗ Dehydrocavidine 38.99 0.81 92043552 CR
MOL030∗ Dehydrocorybulbine 46.97 0.63 101879963 CR
MOL031∗ Dehydrocorydaline 41.98 0.68 34781 CR
MOL032∗ Dehydrocorydalmine 43.9 0.59 3083983 CR
MOL035∗ Demethylcorydalmatine 38.99 0.54 N/A CR
MOL036∗ 13-Methyldehydrocorydalmine 35.94 0.63 25254728 CR
MOL037∗ (1S,8
󸀠R)-6,7-Dimethoxy-2-methylspiro[3,4-dihydroisoquinoline-
1,7󸀠-6,8-dihydrocyclopenta[g][1,3]benzodioxole]-8󸀠-ol 43.95 0.72 21770852 CR
MOL040 Izoteolin 39.53 0.51 133323 CR
MOL041∗ Isocorybulbine 40.18 0.66 12310873 CR
MOL042∗ Leonticine 45.79 0.26 12314123 CR
MOL043∗ 13-Methylpalmatrubine 40.97 0.63 12275616 CR
MOL047∗ N-Methyllaurotetanine 41.62 0.56 6543699 CR
MOL048∗ Norglaucine 30.35 0.56 N/A CR
MOL051∗ Pontevedrine 30.28 0.71 11047165 CR
MOL052∗ Pseudocoptisine 38.97 0.86 15520811 CR
MOL053∗ 24240-05-9 53.75 0.83 185559 CR
MOL055∗ Saulatine 42.74 0.79 185141 CR
MOL057 Stylopine 48.25 0.85 440583 CR
MOL058∗ Tetrahydrocorysamine 34.17 0.86 14315597 CR
MOL059∗ Tetrahydroprotopapaverine 57.28 0.33 40512630 CR
MOL060∗ ST057701 31.87 0.56 6992288 CR
MOL061 2,3,9,10-Tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-8-one 76.77 0.73 10362429 CR
MOL065 Palmatine 64.6 0.65 19009 CR
MOL067 Fumarine 59.26 0.83 4970 CR
MOL068 Isocorypalmine 35.77 0.59 10220 CR
MOL069 Bicuculline 69.67 0.88 10237 CR
MOL071 C09367 47.54 0.69 12441 CR
MOL072 Quercetin 46.43 0.28 5280343 CR
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Table 3: Continued.
Number Molecule name OB (%) DL PubChem CID Herbs
MOL124 Stigmasterol 43.83 0.76 5280794 ASR/CR
MOL148 2,6-Di(phenyl)thiopyran-4-thione 69.13 0.15 11832833 ASR
MOL236 1-Monolinolein 37.18 0.30 6436630 ZR
MOL239 6-Gingerol 35.64 0.16 442793 ZR
MOL274
[(1S)-3-[(E)-But-2-enyl]-2-methyl-4-oxo-1-cyclopent-2-enyl]
(1R,3R)-3-[(E)-3-methoxy-2-methyl-3-oxoprop-1-enyl]-2,2-
dimethylcyclopropane-1-carboxylate
62.52 0.31 5315890 ZR
MOL287 Sexangularetin 62.86 0.3 5281698 ZR
MOL303 Beta-sitosterol 36.91 0.75 222284 ZR/ASR
MOL304 Sitosterol 36.91 0.75 12303645 ZR
∗Compounds only present in CR.
Table 4: Information on 21 potential targets.
Number Protein name Gene name UniProt ID
TAR01 Prostaglandin G/H synthase 2 PTGS2 P35354
TAR02 Sodium channel protein type 5 subunit alpha SCN5A Q14524
TAR03 Muscarinic acetylcholine receptor M3 CHRM3 P20309
TAR04 Muscarinic acetylcholine receptor M1 CHRM1 P11229
TAR05 Muscarinic acetylcholine receptor M4 CHRM4 P08173
TAR06 Delta-type opioid receptor OPRD1 P41143
TAR07 Mu-type opioid receptor OPRM1 P35372
TAR08 Mitogen-activated protein kinase 14 MAPK14 Q16539
TAR09 Alpha-2A adrenergic receptor ADRA2A P08913
TAR10 Muscarinic acetylcholine receptor M2 CHRM2 P08172
TAR11 Alpha-2B adrenergic receptor ADRA2B P18089
TAR12 D(2) dopamine receptor DRD2 P14416
TAR13 Gamma-aminobutyric acid receptor subunit alpha-1 GABBR1 Q9UBS5
TAR14 Metabotropic glutamate receptor 5 GRM5 P41594
TAR15 Metabotropic glutamate receptor 1 GRM1 Q13255
TAR16 Aldose reductase AKR1B1 P15121
TAR17 Amine oxidase [flavin-containing] B MAOB P27338
TAR18 Tumor necrosis factor TNF P01375
TAR19 Cell division control protein 2 homolog CDK1 P06493
TAR20 Amine oxidase [flavin-containing] A MAOA P21397
TAR21 Neuronal acetylcholine receptor protein, alpha-7 chain CHRNA7 P36544
compounds, which are involved in the regulation of central
analgesic effects [33, 34]. Muscarinic acetylcholine receptors,
CHRM3, CHRM1, and CHRM4, corresponded to 30, 28, and
21 compounds, respectively.
3.5. GO Biological Process Enrichment Analysis. The GO
enrichment analysis function of the DAVID platform was
used to study the predicted protein target function. A total
of 25 entries were confirmed in this analysis (𝑃 < 0.05) in
Figure 4. The major biological processes involved G-protein
coupling that regulates smoothmuscle contraction, transmits
chemical synapses, and reacts to toxic substances. These
findings demonstrated that the corresponding targets of
XGDP and the corresponding genes of PD have functionally
similar characteristics.
3.6. Identification of Significant Pathways. The Kyoto Ency-
clopedia of Genes and Genomes (KEGG) pathway enrich-
ment analysis was performed using the functional annotation
tool of DAVIDBioinformatics Resources 6.7. In total, 15 path-
ways were significantly associated with the input set of genes.
To further elucidate the target–pathway mechanisms,
a target–pathway network was constructed on the basis
of all potential targets and their corresponding significant
signaling pathways (Figure 5). As shown in Figure 5, this
network is composed of 34 nodes (15 pathways and 19
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Figure 3: Compound–target network for XGDP for treating PD.The red nodes represent potential drug targets, and the blue nodes represent
active compounds. The edges represent the interaction between them, and the node size is proportional to the degree.
proteins) and 64 interactions. The pink nodes represent
the pathways, the green nodes represent the compounds,
and the edges represent the interactions between them. The
centralization and heterogeneity of the network were found
to be 0.297 and 0.535, respectively. As shown in Figure 5,
the results demonstrate that 13 nondisease pathways out
of 15 pathways enriched within multiple targets of XGDP
could be the key factors contributing to the anti-PD effect,
such as neuroactive ligand-receptor interaction (degree = 13),
calcium signaling pathway (degree = 6), cholinergic synapse
(degree = 5), regulation of actin cytoskeleton (degree = 4),
cAMP signaling pathway (degree = 4), dopaminergic synapse
(degree = 4), retrograde endocannabinoid signaling (degree =
4), gap junction (degree = 4), sphingolipid signaling pathway
(degree = 3), serotonergic synapse (degree = 3), TNF signal-
ing pathway (degree = 3), and estrogen signaling pathway
(degree = 3), and the other pathways interact with at least
2 potential targets. Neuroactive ligand-receptor interaction
should be the crucial analgesic pathway and is regulated by 13
potential targets (OPRM1, DRD2, GABBR1, GRM1, GRM5,
CHRM4, CHRM3, CHRM2, CHRM1, ADRA2A, CHRNA7,
ADRA2B, and OPRD1). In addition, calcium signaling path-
way possesses a wide range of cellular processes including
contraction, exocytosis, and cell proliferation [35]. Calcium
ions are important for cellular signaling and act in signal
transduction resulting from the activation of ion channels or
as a secondmessenger caused by indirect signal transduction
pathways such as G-protein-coupled receptors. Nevertheless,
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cAMP is one of the most common and universal second
messengers and cAMP signaling pathway regulates pivotal
physiologic processes including calcium homeostasis, mus-
cle contraction, metabolism, secretion, cell fate, and gene
transcription [36]. Tumor necrosis factor (TNF), as a critical
cytokine, can induce a wide range of intracellular signal
pathways including inflammation and immunity [37]; the
analgesic effects appeared to be mediated by inhibition of
PTGS2 biosynthesis [25].
4. Discussion
A TCM formula is composed of multiple ingredients and has
a complex mechanism of action, which may be associated
with multiple targets and multiple pathways in humans.
XGDP is a new drug commonly used for treating PD and has
been approved by the China Food and Drug Administration.
In the present study, a network pharmacology approach was
applied to identify the bioactive compounds and significant
pathways of XGDP by using OB and DL evaluation. In this
study, 350 compounds of XGDP were extracted from the
TCMSP database. The results showed that 55 compounds
exhibited favorableOB andDLproperties. Screening revealed
that 53 compounds are the potential active molecules of
XGDP, and these compounds will be selected as candidates
for further study.
Among the 53 active compounds, a few compounds have
been verified to possess multiple pharmacological actions
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including analgesic effects. Particularly, the tetrahydropal-
matine (THP) exerted analgesic effects through blocking
of voltage-activated L-type calcium channel active potas-
sium channels on primary dysmenorrhea [25]. The enan-
tiomer Levo-tetrahydropalmatine (Levo-THP) was synthet-
ically produced by the pharmaceutical industry and has
been marketed worldwide under different brand names as an
alternative drug of analgesics. A recent study reported that
dehydrocorybulbine (DHCB) is effective against inflamma-
tory pain and injury-induced neuropathic pain and causes
no antinociceptive tolerance interaction with D2 receptors
[26, 38]. Eight isoquinoline alkaloids, that is, tetrahydropal-
matine, corydaline, protopine, berberine, palmatine, jatror-
rhizine, coptisine, and dehydrocorydaline, were isolated from
the methanolic extract of the tubers of CR and they also were
acetylcholinesterase inhibitors [39].
In the present study, through analysis of the topological
properties of the compound–target interaction network, we
found that compounds with a high degree and potential
targets that occupy hub positions in the network may play
crucial roles in the pharmacological function of XGDP.
The analysis of the compound–target network showed that
the main active ingredients of XGDP can act on multiple
pathways, consistent with the multicomponent, multitarget,
and integrated regulation characteristics of TCM formulas
[12].
Dysmenorrhea may be related to nitric oxide (NO) [40]
where XGDP can reduce NO levels through the calcium
signaling pathway and arginine and proline metabolism,
whereas the PTGS2 is the target for NSAIDs and PTGS2
(COX-2) specific inhibitors called coxibs for dysmenorrhea
[41]. Notably, 52 compounds among XGDP act on PTGS2.
The endogenous system of opioid receptors (OPRM1 and
OPRD1) is well known for its analgesic potential; XGDP
may treat dysmenorrhea through regulating central analgesic
effects [33, 34]. The CHRM3 are located at many places
Evidence-Based Complementary and Alternative Medicine 11
including smoothmuscleswhere they can cause smoothmus-
cle contraction and increased glandular secretions. XGDP
may relief smooth muscles shrinking by inhibiting CHRM3
receptor. It is interesting that many compounds exhibit
analgesic effects in our study. Therefore, the multidirectional
pharmacological treatment mechanisms of TCM formulas
that act through multiple targets, anti-inflammation anal-
gesia, central analgesia, and relieving smooth muscle con-
traction may be a main therapeutic strategy to treat PD.
On the basis of the potential targets of the 53 compounds,
15 significant pathways associated with 19 potential targets
were obtained. Our study showed that XGDP may exert
its therapeutic effects on PD through neuroactive ligand-
receptor interaction, calcium signaling pathway, cAMP sig-
naling pathway, tumor necrosis factor (TNF) pathway, and so
forth.
Phase II and III clinical trials of XGDP have verified
its analgesic effect on patients with PD. This study further
analyzed the possible chemical compositions that could enter
the bloodstream using systems pharmacology and predicted
the possible targets of the compositions through network
pharmacology, after which GO and pathway enrichment
analysis were conducted on the targets. The major active
ingredients of XGDP can act on several pathways, display-
ing the characteristics of multicomponent, multitarget, and
integrated regulation of TCM compounds. The complex
composition of TCM that acts on distinct targets through
systematic actions in all aspects of disease could achieve the
purpose of disease treatment through mutual coordination.
The constituents of TCM are complex, and these ingre-
dients with different effects and different targets can act on
the various aspects of the disease through multiple systems,
and they interact with each other to produce synergistic
effects [42, 43]. Previous one-target and one-drug model
studies have tended to ignore the relationship between
many diseases [44]. A TCM formula is a multicomponent
and multitarget synergistic system that accounts for this
relationship. Network pharmacology can predict the target
profiles and pharmacological actions of herbal compounds.
In our study, network construction approaches were used
to identify the bioactive compounds of XGDP and their
potential targets and we preliminarily explored the analgesia
mechanisms of XGDP for PD. For the complexity of TCM,
potential targets of the 53 main compounds were further
experimentally validated for their roles in relief of analgesia.
5. Conclusions
Among 331 compounds, a total of 53 bioactive compounds in
XGDP with 15 significant pathways were identified through
network analysis. Thus, the mechanism of action of XGDP
for PD involves multiple compounds, targets, and pathways.
The therapeutic effects of XGDP on PD may be dependent
on the regulation of the targets related to anti-inflammation
analgesia, central analgesia, and relieving smooth muscle
contraction. The network pharmacology approaches devel-
oped in our study provide an alternative strategy for the
comprehensive understanding of the therapeutic effects of
XGDP on PD.
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